
|Videos|April 6, 2016
How Renal Function and Comorbidities Affect Dosing for NOACs
John Fanikos, RPh, MBA, director of pharmacy at Brigham and Women's Hospital, discusses how a patient's renal function and comorbidities affect dosing regimens for novel oral anticoagulants.
Advertisement
John Fanikos, RPh, MBA, director of pharmacy at Brigham and Women's Hospital, discusses how a patient’s renal function and comorbidities affect dosing regimens for novel oral anticoagulants.
This video was recorded at APhA's 2016 Annual Meeting and Exposition in Baltimore, Maryland.
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
TrumpRx Launches, Offering Cash-Paying Patients Discounted Drugs
2
Pharmacist Takeover: CAR T Therapy Signals a Shift in ALL Treatment
3
SGLT2 Inhibitors in T2D Lower 5-Year Risk of CKD and Acute Kidney Injury
4
Q&A: How Pharmacists Can Address Structural Barriers in Obesity Care
5


























